Notice of Intent to Publish a Funding Opportunity Announcement for Accelerating the Pace of Substance Use Research Using Existing Data (R21 Clinical Trial Not Allowed)
ID: 356831Type: Forecasted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Award Range

$0 - $200K

Eligible Applicants

Others

Funding Category

Health

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes
Timeline
    Description

    The National Institutes of Health (NIH) is preparing to publish a Notice of Funding Opportunity (NOFO) aimed at accelerating substance use research through the utilization of existing data, specifically under the R21 grant mechanism. This initiative seeks to foster innovative research projects that leverage pre-existing datasets to enhance understanding and treatment of substance use disorders. The total estimated funding for this program is $2 million, with an award ceiling of $200,000 per project and an anticipated three awards to be made. Interested applicants should note that the NOFO is expected to be published in Fall 2024, with applications due in Spring 2025, and the estimated award date is set for April 1, 2026.

    Point(s) of Contact
    No information provided.
    Files
    No associated files provided.
    Similar Opportunities
    Accelerating the Pace of Substance Use Research Using Existing Data (R21 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Accelerating the Pace of Substance Use Research Using Existing Data," aimed at supporting innovative analyses of existing datasets related to substance use behaviors, including alcohol, tobacco, and illicit drugs, and their connections to health outcomes such as HIV. This grant, classified as an R21 Clinical Trial Not Allowed, encourages applicants to utilize existing social science, behavioral, administrative, and neuroimaging data to enhance understanding of drug use behaviors, their consequences, and effective prevention and treatment strategies. A total of $2 million is available for projects over a two-year period, with individual application budgets capped at $275,000. Interested applicants must submit their proposals electronically through Grants.gov by December 3, 2027, and can direct inquiries to grantsinfo@nih.gov for further information.
    Notice of Intent to Publish a Funding Opportunity Announcement for Accelerating the Pace of Substance Use Research Using Existing Data (R01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is forecasting a funding opportunity announcement for research aimed at accelerating the pace of substance use research using existing data, specifically under the R01 grant mechanism. This initiative seeks to promote innovative research projects that leverage existing datasets to enhance understanding and treatment of substance use disorders, with the goal of fostering meaningful collaborations among researchers. The estimated total program funding is $2 million, with approximately three awards expected to be made, and the anticipated application due date is in Spring 2025, following the publication of the Notice of Funding Opportunity in Fall 2024. For further details, potential applicants should prepare to submit their proposals by the estimated close date of June 17, 2025, with awards expected to be announced by April 1, 2026.
    Accelerating the Pace of Substance Use Research Using Existing Data (R01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Institute on Drug Abuse (NIDA), has announced a funding opportunity titled "Accelerating the Pace of Substance Use Research Using Existing Data." This initiative invites applications that propose innovative analyses of existing social science, behavioral, administrative, and neuroimaging data to investigate the etiology and epidemiology of substance use behaviors and related disorders, including HIV prevention and health service utilization. The program aims to leverage public datasets to enhance understanding of substance use trajectories and effective prevention strategies, particularly focusing on underrepresented populations and health disparities. A total funding commitment of $2 million is available for fiscal year 2026, with applications due by January 25, 2025. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov.
    Mechanism for Time-Sensitive Substance Use Research (R21 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Mechanism for Time-Sensitive Substance Use Research" under the National Institute on Drug Abuse (NIDA). This grant, designated as R21, aims to support pilot, feasibility, and exploratory research addressing urgent issues in substance use epidemiology and health services, particularly in response to sudden increases in substance misuse and emerging public health challenges. Eligible applicants include a wide range of entities such as educational institutions, governmental bodies, and nonprofit organizations, with a budget cap of $275,000 over two years. Interested parties must submit their applications by September 9, 2027, and can direct inquiries to grantsinfo@nih.gov for further information.
    Exploratory Clinical Neuroscience Research on Substance Use Disorders (R61/R33 Basic Experimental Studies with Humans (BESH) Required)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a Notice of Funding Opportunity (NOFO) for exploratory clinical neuroscience research focused on substance use disorders (SUD) through the R61/R33 phased innovation award mechanism. This funding opportunity aims to support clinical research proposals that investigate the neurobiological mechanisms underlying SUD, allowing for up to five years of funding, with the R61 phase dedicated to initial concept testing and the R33 phase contingent upon achieving specific milestones. The initiative is crucial for advancing understanding of substance abuse impacts in the U.S., encouraging innovative research on topics such as neural circuitry and cognitive factors influencing addiction. Interested applicants, including various educational and nonprofit institutions, can find more details and submit applications by the closing date of May 7, 2026, with no cost-sharing requirement. For further inquiries, contact NIH Grants Information at grantsinfo@nih.gov or visit the additional information link at https://grants.nih.gov/grants/guide/pa-files/PAR-23-158.html.
    Mechanistic Research on Neuromodulation for Substance Use Disorders Treatment (R61/R33 Basic Experimental Studies with Humans Required)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Mechanistic Research on Neuromodulation for Substance Use Disorders Treatment," aimed at encouraging clinical research to explore novel non-invasive brain stimulation (NIBS) targets for treating substance use disorders (SUD). This initiative seeks applications for exploratory and developmental studies that will identify and validate neurobiological, cognitive, and behavioral responses to NIBS, with the goal of understanding mechanisms that could lead to reduced cravings and substance use. The NIH plans to allocate $1.5 million in funding for fiscal years 2024-2026, with an award ceiling of $500,000 per project phase, and key submission dates starting December 16, 2023. Interested applicants can find more information and guidelines at the NIH grants website or contact NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    Mechanism for Time-Sensitive Drug Abuse Research (R21 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a grant opportunity titled "Mechanism for Time-Sensitive Drug Abuse Research," aimed at supporting urgent exploratory research in substance use epidemiology and health services. This funding initiative focuses on five priority areas, including responses to sudden spikes in drug use, emerging marijuana trends, and time-sensitive issues related to prescription drug abuse and addiction services within the evolving healthcare system. Eligible applicants include a wide range of organizations such as higher education institutions, non-profits, and state or local governments, with funding available up to $275,000 over a two-year period. Interested parties should note that the application deadline is January 14, 2025, and are encouraged to consult with NIH contacts for alignment with the FOA’s priorities. For further details, applicants can refer to the full announcement at http://grants.nih.gov/grants/guide/pa-files/PAR-22-027.html or contact the NIH OER Webmaster at OERWebmaster03@od.nih.gov.
    Targeting Inflammasomes in HIV and Substance Use (R21 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Targeting Inflammasomes in HIV and Substance Use (R21 Clinical Trial Not Allowed)" aimed at exploring the role of inflammasomes in the context of HIV infection and substance use disorders. This R21 exploratory grant encourages research into the mechanisms of inflammasome activation and their association with neurocognitive disorders in individuals affected by HIV and substance use, with a focus on identifying molecular markers and potential therapeutic innovations. The total funding available is up to $2 million over two years, with applications opening on February 13, 2024, and a submission deadline of March 13, 2025. Interested applicants can find more information and guidelines at the NIH grants website or contact NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    Notice of Intent to Publish a Funding Opportunity Announcement for NIDA REI: Reaching Equity at the Intersection of HIV and Substance Use: Novel Approaches to Address HIV Related Health Disparities in Underserved Racial and/or Ethnic Populations (R01)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is preparing to publish a Notice of Funding Opportunity (NOFO) for the initiative titled "NIDA REI: Reaching Equity at the Intersection of HIV and Substance Use," aimed at addressing HIV-related health disparities in underserved racial and/or ethnic populations. This funding opportunity will solicit research applications that propose novel approaches to tackle these critical health issues, with a focus on fostering meaningful collaborations among applicants. The estimated total program funding for this initiative is $2,000,000, with the NOFO expected to be published in Summer 2025 and applications due in Winter 2025. Interested researchers should prepare to submit their proposals by the anticipated deadlines, with awards expected to be made by July 1, 2026.
    Notice of Intent to Publish a Funding Opportunity Announcement for Tobacco, Alcohol, and Cannabis Policy Research for Health Equity (R21 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is preparing to publish a Notice of Funding Opportunity (NOFO) for pilot and exploratory research projects focused on health equity related to tobacco, alcohol, and cannabis use. The initiative aims to investigate disparities in exposure and usage of these substances by examining new or adapted policies in the U.S., with the goal of advancing equitable health policies. This funding opportunity will utilize the R21 grant mechanism, which supports early-stage research, and is expected to be published in September 2024, with the first application deadline in March 2025. Interested applicants should prepare their proposals in advance, as the estimated award date is December 1, 2025, and further details, including a pre-application webinar, will be announced following the NOFO publication.